Bicalutamide and RO4929097 in Treating Patients With Previously Treated Prostate Cancer
Status:
Terminated
Trial end date:
2012-11-01
Target enrollment:
Participant gender:
Summary
This partially randomized phase II trial is studying how well giving bicalutamide together
with RO4929097 works in treating patients with previously treated prostate cancer. Androgens
can cause the growth of prostate cancer cells. Antihormone therapy, such as bicalutamide, may
lessen the amount of androgens made by the body. RO4929097 may stop the growth of tumor cells
by blocking some of the enzymes needed for cell growth. Giving bicalutamide together with
RO4929097 may be an effective treatment for prostate cancer